Celebrity Inventors
Lawrence Welk, the bandleader who entertained millions of Americans over a generation of broadcasting his TV show, once received a patent: for a music-themed design of an ashtray.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8188100 | Adenosine derivatives as A2A receptor agonists A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, formula (1), or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U1, U2, R1a, R1b, R2 and R3 | 05/29/2012 |
| 8143265 | Method of treating atherosclerosis A method of treating atherosclerosis in a subject is carried out by administering the subject 2-aminopurine or a pharmaceutically salt thereof in a treatment effective amount. Optionally, the subject may also be administered an additional hypolipidemic agent. Compos... | 03/27/2012 |
| 8080555 | Purine derivatives and their use for treatment of autoimmune diseases Compounds useful in the treatment of autoimmune disease are described by the following general formula: n=0-2 m=0-2 m is not necessarily equal to n; ... | 12/20/2011 |
| 8058281 | Use of adenine-derived compounds for the treatment of lupus The present invention is directed to a method of treating systemic lupus erythematosus comprising administering a compound of formula (I) wherein R1 is selected from the group consi... | 11/15/2011 |
| 7868011 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus The present invention provides methods for suppressing autoimmunity in a patient in need of treatment for systemic lupus erythematosus by administering to the patient an effective amount of methyl 4-(Adenin-9-yl)-2-hydroxybutanoate or pharmaceutically acceptable sal... | 01/11/2011 |
| 7825126 | Purine derivatives as A3 and A1 adenosine receptor agonists Disclosed are (N)-methanocarba adenine nucleosides of the formula: as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleoside... | 11/02/2010 |
| 7517887 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowerin... | 04/14/2009 |
| 7517888 | Aadenosine receptor antagonists Disclosed are A1 adenosine receptor antagonists having the general formula The compounds are useful for treating various disease states, in particular disease states for which diuretic treatment is appropriate.... | 04/14/2009 |
| 7439240 | Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity The present invention therefore provides a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases ... | 10/21/2008 |
| 7393855 | 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and pyrimidines as antiviral agents Compounds which are active against viruses have the following formulas: wherein B is a purine or pyrimidine heterocyclic ring or base. In a preferred embodiment, the purine include 6-aminopurine (adenine), 6-hydroxypurine (... | 07/01/2008 |
| 7388002 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases Compounds represented by the formula: A is (CH2)nR2, —CH═CH2, CH2—CH═CH2, O(CH2)nR2, CH(OH)CH3, CH(OH)... | 06/17/2008 |
| 7342021 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein. ... | 03/11/2008 |
| 7335654 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein. ... | 02/26/2008 |
| 7332486 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein. ... | 02/19/2008 |
| 7319101 | COMT inhibitors for the treatment of depression and impaired cognition The present invention relates to compounds of formula I wherein R1 is as defined in the specification and to esters thereof which are hydrolyzable under physiological conditions and to the ph... | 01/15/2008 |
| 7317018 | Anti-inflammatory medicament The use of adenosine-5′-triphosphate-2′,3′-dialdehyde (oATP) as a medicament useful for the treatment of inflammatory conditions is disclosed. ... | 01/08/2008 |
| 7294619 | Lipid analogs for inhibiting the activity of hepatitis B antigen The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the ... | 11/13/2007 |
| 7294620 | Lipid analogs for inhibiting HIV-1 activity The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the ... | 11/13/2007 |
| 7294621 | Lipid analogs for combating tumors The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the ... | 11/13/2007 |
| 7279483 | Famciclovir monohydrate Famciclovir monohydrate and its pharmaceutical use. ... | 10/09/2007 |
| 7279482 | Heterocyclic compound based on N-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds Heterocyclic derivatives based on N6-substituted adenine of, e.g.,a formula: wherein R2 is hydrogen, R6 is R6′-X, X is —NH—, and R6′ is substituted phenyl or substituted benzyl. The derivatives... | 10/09/2007 |
| 7273864 | Compositions and methods for inducing osteogenesis The present invention provides compositions and methods for differentiating and transdifferentiating mammalian cells into cells of an osteoblast lineage, using compounds of the following formula: wherein R4 ... | 09/25/2007 |
| 7268230 | Quinazoline compounds The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is —O—, —NH— or —S—; n is 0-5; m is 0-3; R1 and R2 are defined herein including groups: (i) ... | 09/11/2007 |
| 7265111 | Adenosine analogues and their use as pharmaceutical agents The present invention relates to compounds according to the general formula (I) wherein X is selected from the group consisting of wherein n and p are indepe... | 09/04/2007 |
| 7256196 | Purine cytokine inhibitors The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions c... | 08/14/2007 |
| 7253175 | Method for treating athlete's foot A method of treating a patient having a fungal infection comprises administering an effective fungal infection treatment amount of an antiviral agent, such as valacyclovir, to eliminate the symptoms of the fungal infection. ... | 08/07/2007 |
| 7253154 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors The invention relates to compounds of the following formula (I) or their salts: in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which m... | 08/07/2007 |
| 7241890 | Purine analogs having HSP90-inhibiting activity Novel purine compounds of Formula I. and tautomers, pharmaceutically acceptable salts, and prodrugs thereof, wherein X is S, S(O), or S(O)2; and O is selected from alkyl, cycloalkyl, arylalkyl, aryl, h... | 07/10/2007 |
| 7238700 | Aadenosine receptor antagonists Disclosed are novel A2B adenosine receptor antagonists of Formula I: A compound of the formula: wherein: R1 is... | 07/03/2007 |
| 7219505 | Control stability system for moist air dehumidification units and method of operation A system and humidity control method is provided for a multi-stage cooling system having two or more refrigerant circuits that balances humidity control and cooling demand. Each refrigerant circuit includes a compressor, a condenser and an evaporator. A hot gas rehe... | 05/22/2007 |
| 7217716 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists Compounds represented by Formula (I): (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain ... | 05/15/2007 |
| 7217702 | Selective antagonists of A2A adenosine receptors Selective antagonists of A2A adenosine receptors like those of formula I are provided, wherein Y forms a ring. The novel A2A blockers are useful for the treatment of Parkinsons disease and o... | 05/15/2007 |
| 7214665 | 2-propynyl adenosine analogs having Aagonist activity and compositions thereof The invention provides compounds having the following general formula (I): wherein X, R1, R2, R7 and Z are as described here. ... | 05/08/2007 |
| 7196093 | Reversible inhibitors of SAH hydrolase and uses thereof 1. The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowe... | 03/27/2007 |
| 7189730 | Aadenosine receptor antagonists Disclosed are novel A2A adenosine receptor antagonists of the formula: wherein: R1 is optionally substituted aryl or optionally substituted heteroaryl; | 03/13/2007 |
| 7183268 | 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents Compounds which are active against viruses have the following Formulas: wherein B is 2-aminopurine-9-yl, which may be unsubstituted or substituted in the 6 position with NHR1, ... | 02/27/2007 |
| 7173038 | Quinazoline derivatives as VEGF inhibitors The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C | 02/06/2007 |
| 7160889 | Quinazoline compounds The invention concerns quinazoline derivatives of Formula (I) wherein ring A is phenyl or a 5-or 6-membered heterocyclic ring which may be saturated, partially saturated or unsaturated and may be aromatic or non-... | 01/09/2007 |
| 7157449 | Medicament for the treatment of diseases caused by parasitic protozoa The present invention relates to the use of an inhibitor of CTP synthetase, such as a glutamine analogue, and a substance capable of suppressing toxic effects thereof in vivo, in the manufacture of a medicament for the treatment of a disease caused by a parasitic pr... | 01/02/2007 |
| 7148257 | Methods of treating mesothelioma with suberoylanilide hydroxamic acid Methods for treating mesothelioma comprising administering the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) are disclosed. ... | 12/12/2006 |
